Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo

Autoimmunity Reviews

Volumn 6, Issue 3, 2007, Pages 138-142

  Kemp, E Helen ^a   Gavalas, Nikos G ^a   Gawkrodger, David J ^b   Weetman, Anthony P ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Autoantibody; Autoimmunity; Melanocyte; Vitiligo

Indexed keywords

ALPHA INTERMEDIN; AUTOANTIBODY; MELANIN CONCENTRATING HORMONE; MELANOCORTIN RECEPTOR;

AUTOIMMUNE DISEASE; CELL MEDIATED CYTOTOXICITY; DEPIGMENTATION; DIAGNOSTIC TEST; HUMAN; IMMUNIZATION; MELANOCYTE; NONHUMAN; PIGMENT CELL; REVIEW; SKIN DISEASE; T LYMPHOCYTE; VITILIGO;

AUTOANTIBODIES; HUMANS; MELANOCYTES; VITILIGO;

EID: 33846569338     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.09.010     Document Type: Review

References (40)

1. Howitz J., Brodthagen H., Schwartz M., and Tomsen K. Prevalence of vitiligo: epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol 113 (1977) 47-52
2. Majumder P.P., Nordlund J.J., and Nath S.K. Pattern of familial aggregation of vitiligo. Arch Dermatol 129 (1993) 994-998
3. Ortonne J.P., Mosher D.B., and Fitzpatrick T.B. Vitiligo and other hypomelanoses of hair and skin. In: Ortonne J.P., Mosher D.B., and Fitzpatrick T.B. (Eds). Topics in dermatology (1983), Plenum Medical Book Co., New York 257-258
4. Kent G., and Al' Abadie M.S.K. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol 35 (1996) 895-898
5. Taeib A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res 13 Supplement 8 (2000) 41-47
6. Pawelek J., Korner A., and Bergstrom A. New regulation of melanin biosynthesis and autodestruction of melanoma cells. Nature 286 (1980) 617-619
7. Nordlund J.J., and Lerner A.B. Vitiligo. It is important. Arch Dermatol 118 (1982) 5-8
8. Schallreuter K.U., Wood J.M., and Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 97 (1991) 1081-1085
9. Ochi Y., and DeGroot L.J. Vitiligo in Graves' disease. Ann Intern Med 71 (1969) 935-940
10. Naughton G.K., Eisinger M., and Bystryn J.-C. Antibodies to normal human melanocytes in vitiligo. J Exp Med 158 (1983) 246-251
11. Ogg G.S., Dunbar P.R., Romero P., Chen J.-L., and Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188 (1998) 1203-1208
12. Le Poole I.C., Das P.K., van den Wijngaard R.M.J.G.J., Bos J.D., and Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 2 (1993) 145-153
13. Farrokhi S., Farsangi-Hojjat M., Noohpisheh M.K., Tahmasbi R., and Rezaei N. Assessment of the immune system in 55 Iranian patients with vitiligo. J Eur Acad Dermatol Venereol 19 (2005) 706-711
14. Naughton G.K., Eisenger M., and Bystryn J.-C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 81 (1983) 540-542
15. Harning R., Cui J., and Bystryn J.-C. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 97 (1991) 1078-1080
16. Naughton G.K., Reggiardo M.D., and Bystryn J.-C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 15 (1986) 978-981
17. Yu H.S., Kao C.H., and Yu C.L. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 100 (1993) 823-828
18. Aronson P.J., and Hashimoto K. Association of IgA anti-melanoma antibodies in the sera of vitiligo patients with active disease. J Invest Dermatol 88 (1987) 475
19. Cui J., Harning R., Henn M., and Bystryn J.-C. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 98 (1992) 162-165
20. Cui J., Arita Y., and Bystryn J.-C. Characterisation of vitiligo antigens. Pigment Cell Res 8 (1995) 53-59
21. Park Y.K., Kim N.S., Hann S.K., and Im S. Identification of autoantibody to melanocytes and characterisation of vitiligo antigen in vitiligo patients. J Dermatol Sci 11 (1996) 111-120
22. Rocha I.M., Oliveira L.J., De Castro L.C., De Araujo Pereira L.I., Chaul A., Guerra J.G., et al. Recognition of melanoma cell antigens with antibodies present from patients with vitiligo. Int J Dermatol 39 (2002) 840-843
23. Song Y.H., Connor E., Li Y., Zorovich B., Balducci P., and Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet 344 (1994) 1049-1052
24. Baharav E., Merimski O., Shoenfeld Y., Zigelman R., Gilbrund B., and Yecheskel G. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 105 (1996) 84-88
25. 35S-labelled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 109 (1997) 69-73
26. Xie Z., Chen D.L., Jiao D., and Bystryn J.-C. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 135 (1999) 417-422
27. Kemp E.H., Gawkrodger D.J., Watson P.F., and Weetman A.P. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 109 (1997) 495-500
28. Okamoto T., Irie R.F., Fujii S., Huang S.K.S., Nizze A.J., Morton D.L., et al. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111 (1998) 1034-1039
29. Kemp E.H., Waterman E.A., Gawkrodger D.J., Watson P.F., and Weetman A.P. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 139 (1998) 798-805
30. Kemp E.H., Gawkrodger D.J., Watson P.F., and Weetman A.P. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 114 (1998) 333-338
31. Hedstrand H., Ekwall O., Olsson M.J., Landgren E., Kemp E.H., Weetman A.P., et al. The transcription factors SOX9 and SOX10 are melanocyte autoantigens related to vitiligo in autoimmune polyendocrine syndrome type 1. J Biol Chem 276 (2001) 35390-35395
32. Kemp E.H., Waterman E.A., Hawes B.E., O'Neill K., Gottumukkala R., Gawkrodger D.J., et al. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 109 (2002) 923-930
33. Gottumukkala R.V.S.R.K., Waterman E.A., Herd L.M., Gawkrodger D.J., Watson P.F., Weetman A.P., et al. Autoantibodies in vitiligo patients recognise multiple domains of the melanin-concentrating hormone receptor. J Invest Dermatol 121 (2003) 765-770
34. Norris D.A., Kissinger R.M., Naughton G.K., and Bystryn J.-C. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocyes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90 (1988) 783-789
35. Gilhar A., Zelickson B., Ulman Y., and Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 105 (1995) 683-686
36. Gottumukkala R.V.S.R.K., Gavalas N.G., Akhtar S., Metcalfe R.A., Gawkrodger D.J., Haycock J.W., et al. Function blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. Lab Invest 86 (2006) 781-789
37. Fishman P., Azizi E., Shoenfeld Y., Sredni B., Yesheskel G., Ferrone S., et al. Vitiligo autoantibodies are effective against melanoma. Cancer 72 (1993) 2365-2369
38. Hoogduijn M.J., Ancans J., Suzuki I., Estdale S., and Thody A.J. Melanin-concentrating hormone and its receptor are expressed and functional in human skin. Biochem Biophys Res Commun 296 (2002) 698-701
39. Norris D.A., Capin L., Muglia J.J., Osborn R.L., Zerbe G.O., Bystryn J.-C., et al. Enhanced susceptibility of melanocytes to different immunologic effector mechanisms in vitro: potential mechanisms for post-inflammatory hypopigmentation and vitiligo. Pigment Cell Res 1 (1988) 113-123 [Supplement]
40. Oyarbide-Valencia K., van den Boorn J.G., Denman C.J., Li M., Carlson J.M., Hernandez C., et al. Therapeutic implications of autoimmune vitiligo cells. Autoimmun Rev 5 (2006) 486-492